Sage Therapeutics (SAGE) - Get SAGE Therapeutics, Inc. Report led biotech movers Friday morning, after its CEO made an erroneous comment during an interview about its depression drug, Thursday after the close. 

Sage spiked 8.9% Thursday on the comment, hitting $62.75 per share. CEO Jeff Jonas said the company is on top of everyone's M&A list in an interview with Bloomberg radio. 

The company issued a statement  after the stock pop, saying Sage is not in any talks to sell. As a result, Sage's stock was correcting its Thursday pop Friday morning, falling 4.16% to $60.14 per share. 

Novavax (NVAX) - Get Novavax, Inc. Report was also falling Friday morning. The company's shares fell 1.28% to $1.54 per share Friday ahead of the market's open. This continued the vaccine company's Thursday fall of 3.7%. It closed at $1.56 per share Thursday. 

TheStreet Recommends

Meanwhile, Cytokinetics (CYTK) - Get Cytokinetics, Incorporated Report shares were flying high Friday. The company was up 7.5% ahead of market's open, shares hitting $12.15 apiece. This was after Cytokinetics, a muscle therapy company, reported better-than-expected fourth-quarter earnings. Cytokinetics had a profit of 16 cents per share, as compared to analysts' expectations of a loss of 27 cents a share. 

Acadia Pharmaceuticals (ACAD) - Get ACADIA Pharmaceuticals Inc. Report was falling Friday morning, hitting $38.45 per share. The Parkinson's disease biotech company fell nearly 2% ahead of market's open. Acadia was the target of takeout rumors earlier this week. However, TheStreet'sAdam Feuerstein was skeptical on those rumors.